Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, 143 Shimokasuya, Isehara, 259-1193, Japan.
Mod Rheumatol. 2012 Aug;22(4):625-9. doi: 10.1007/s10165-011-0558-9. Epub 2011 Nov 29.
Anti-clinically amyopathic dermatomyositis (CADM)-140/MDA5 autoantibodies are specifically detected in patients with dermatomyositis and are known to have a strong association with rapidly progressive interstitial lung disease (RP-ILD). Here we report an amyopathic dermatomyositis (ADM) patient who developed RP-ILD characterized by elevated anti-CADM-140/MDA5 titer. Respiratory symptoms gradually improved, and anti-CADM-140/MDA5 titer decreased in parallel to below the cutoff level. It may be useful to quantify CADM-140-specific autoantibodies for monitoring disease activity in patients with ADM and RP-ILD.
抗临床型皮肌炎 140/MDA5 自身抗体特异性存在于皮肌炎患者中，与快速进展性间质性肺病（RP-ILD）密切相关。本文报道了一例皮肌炎患者发生 RP-ILD，其特征为抗 CADM-140/MDA5 滴度升高。患者的呼吸道症状逐渐改善，抗 CADM-140/MDA5 滴度随之平行下降，低于临界值。定量检测 CADM-140 特异性自身抗体可能有助于监测皮肌炎合并 RP-ILD 患者的疾病活动度。
